End of coverage

From 5th February, we will no longer include in our research universe:Adaptimmune, ALK, argenx, Autolus, Cellectis, Galapagos, Hansa Biopharma, Heidelberg Pharma, Immatics, Immunocore, Ipsen, Moonlake Immunotherapeutics, Pharvaris, UCB, Vivoryon Therapeutics, Zealand Pharma, Nicox, GenSight Biologi

Adaptimmune Therapeutics Plc: 4 directors

Four Directors at Adaptimmune Therapeutics Plc sold 59,468 shares at between 0.847USD and 0.848USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...

Coverage update

Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte

Conference updates: takeaways from ASCO and ISCT

We wrap up the past conference-filled weeks with a summary of the main takeaways from our coverage. From the International Society for Cell & Gene Therapy (ISCT) meeting, we point out i) Cellectis preclinical updates, and ii) a KOL dinner we hosted with Dr Bruce Levine discussing how to improve

Transfer of coverage

from 1st June the cover of the following companies will be transferred to Ingrid GafanhaoADAPTIMMUNE THERAPEUTICSBIONTECHHEIDELBERG PHARMAIMMATICSIMMUNOCORE HOLDINGSINNATE PHARMAONXEOOSE IMMUNOTRANSGENE

Bryan, Garnier & Co Healthcare Daily | Adaptimmune, Immunocore

Bryan, Garnier & Co Consumer Daily | Food Retail, Just Eat, Brunello C...

Broad immune engagement by afami-cel presented at AACR

The company presented additional translational data at AACR, showing that afami-cel induced peripheral and tumoral innate and adaptive immune responses in patients with SyS and MRCLS (link). Notably, following afami-cel infusion, a greater tumoral immune infiltrate was demonstrated at the gene and

Bryan, Garnier & Co Healthcare Daily | HS KOL Call, ABVX, ADAP, ALSEN

Settling GSK breakup

Adaptimmune announced additional details regarding the terms for the transfer of PRAME and NY-ESO-1 programs from GSK. Adaptimmune gained back the rights for lete-cel (NY-ESO-1-targeting TCR T therapy), next-generation NYESO CD8 and NYESO TGF, as well as preclinical PRAME-targeting programs followi

Pioneering TCR T cell therapy

We view Adaptimmune as one of the leaders in the TCR T space due to: i) initiated BLA submission for the lead asset, afami-cel, in synovial sarcoma, which could secure the first-ever approval for TCR-T therapy; ii) while afami-cel provided solid validation, the next generation program, ADP-A2M4CD8,

TCR therapeutics coming of age

With the opportunity to tap into the intracellular target universe and efficient TCR signalling, TCR-based therapies could reach beyond other immunotherapeutics. TCR-based therapeutics showed durable clinical responses in hard-to-treat solid tumours, a significant achievement and a sign of maturity

ADAPTIMMUNE THERA sees an upgrade to Slightly Negative thanks to a bet...

The independent financial analyst theScreener just awarded an improved star rating to ADAPTIMMUNE THERA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date February 11,...